Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma

Autor: Jin M, Jiang ZQ, Qin JH, Qin HX, Jiang KW, Ya HX, Gu J, Gui MR, Li YH, Xu LK, Fu HX, Xiao XH, Li SQ

Publikováno v: Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2309-2320 (2024)

Ming Jin,1,* Zhi-qing Jiang,2,* Jia-hui Qin,3,* Hui-xia Qin,4,* Kai-wen Jiang,3,* Hou-xiang Ya,3 Jing Gu,3 Mo-rui Gui,5 Yao-hua Li,3 Long-kuan Xu,6 Hai-xiao Fu,6 Xu-hua Xiao,7 Shu-qun Li3 1Department of Vascular Intervention, Affi

Externí odkaz: https://doaj.org/article/de755f3d18494613bb0939e02f5709e0

Elevated Risk of Adverse Prognosis in Patients with T2-3 Stage Breast Cancer Exhibiting Non-Pathological Complete Response Following Neoadjuvant Chemotherapy: Significance of Regenerating Islet-Derived Family Member 4

Autor: Li F, Chen CG, Wei JF, Lin JW, Dou ZA, Shen J, Li SQ

Publikováno v: Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 595-610 (2024)

Fan Li,1,* Chuan-Guo Chen,2,* Jiao-Fei Wei,1,3 Jia-Wen Lin,4 Zi-Ang Dou,3,4 Jun Shen,1 Shu-Qin Li1,3,4 1Department of Breast Surgery, the First People’s Hospital of Lianyungang, The Affiliated Hospital of XuZhou Medical University, Lianyung

Externí odkaz: https://doaj.org/article/b158204a78dd4eccb09ab50d26d75e74

Patterns, Risk Factors, and Outcomes of Recurrence After Hepatectomy for Hepatocellular Carcinoma with and without Microvascular Invasion

Autor: Yu Y, Wang XH, Hu WJ, Chen DH, Hu ZL, Li SQ

Publikováno v: Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 801-812 (2024)

Yang Yu,1,* Xiao-Hui Wang,2,* Wen-Jie Hu,1 De-Hua Chen,1 Zi-Li Hu,3 Shao-Qiang Li1 1Hepatic Pancreatobiliary Surgery Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, People’s Republic of China; 2Department o

Externí odkaz: https://doaj.org/article/471a66f1777741cb8b5c478d5ea4b801

Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

Autor: Li SQ, Wu JY, Xie H, Li JH, Zeng ZX, Fu YK, Liu DY, Li H, Chen WZ, Huang JY, Yan ML

Publikováno v: Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 1799-1811 (2023)

Shu-Qun Li,1– 3,* Jun-Yi Wu,1,2,* Jia-Yi Wu,1,2,* Huang Xie,4,* Jin-Hai Li,1,2 Zhen-Xin Zeng,1,2 Yang-Kai Fu,1,2 De-Yi Liu,1,2 Han Li,1,2 Wei-Zhao Chen,1,2 Jing-Yao Huang,4 Mao-Lin Yan1,2 1Department of Hepatobiliary Pancreatic Surg

Externí odkaz: https://doaj.org/article/0f7cfc56fd304e70bcd76b1b369993e0

Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.

Autor: Li SQ; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Yu CZ; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Xu LP; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Wang Y; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Zhang XH; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Chen H; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Chen YH; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Wang FR; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Sun YQ; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Yan CH; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Lv M; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Mo XD; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Liu YR; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Liu KY; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Zhao XS; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Zhao XY; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China., Huang XJ; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Peking-Tsinghua Center for Life Sciences, Beijing, China.; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China., Chang YJ; Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. rmcyj@bjmu.edu.cn.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Nov 16. Date of Electronic Publication: 2024 Nov 16.